Back To Index << Back To Terminology

# Value Set epSOSActiveIngredient 2017‑11‑07 14:06:21

This terminology is a snapshot as of 2026‑02‑11 10:48:51. Terminologies may evolve over time. If you need recent (dynamic) versions of this terminology, please retrieve it from the source.
Id | 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 | Effective Date | 2017‑11‑07 14:06:21 Other versions this id: eHDSIActiveIngredient202602 - as of 2026‑02‑06 15:15:00 eHDSIActiveIngredient202502 - as of 2025‑02‑17 15:15:00 eHDSIActiveIngredient202401 - as of 2024‑01‑25 16:10:00 eHDSIActiveIngredient202301 - as of 2023‑01‑17 16:05:00 eHDSIActiveIngredient202201 - as of 2022‑01‑31 16:00:00 eHDSIActiveIngredient202104 - as of 2021‑04‑19 15:45:00 eHDSIActiveIngredient202006 - as of 2020‑06‑17 11:51:00 eHDSIActiveIngredient202004 - as of 2020‑04‑23 15:10:00 epSOSActiveIngredient201912 - as of 2019‑12‑23 16:20:21 epSOSActiveIngredientJanuary 2010 - as of 2013‑06‑03
Status | Deprecated | Version Label | 201711
Name | epSOSActiveIngredient | Display Name | epSOSActiveIngredient
Description | epSOSActiveIngredient
Source Code System | 2.16.840.1.113883.6.73 - WHO Anatomical Therapeutic Chemical classification - FHIR: http://www.whocc.no/atc - HL7 V2: WC
Level/ Type | Code | Display Name | Code System | Designations | Description
--- | --- | --- | --- | --- | ---
0‑L | A | ALIMENTARY TRACT AND METABOLISM | WHO Anatomical Therapeutic Chemical classification |  | ALIMENTARY TRACT AND METABOLISM
0‑L | A01 | STOMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification |  | STOMATOLOGICAL PREPARATIONS
0‑L | A01A | STOMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification |  | STOMATOLOGICAL PREPARATIONS
0‑L | A01AA | Caries prophylactic agents | WHO Anatomical Therapeutic Chemical classification |  | Caries prophylactic agents
0‑L | A01AA01 | sodium fluoride | WHO Anatomical Therapeutic Chemical classification |  | sodium fluoride
0‑L | A01AA02 | sodium monofluorophosphate | WHO Anatomical Therapeutic Chemical classification |  | sodium monofluorophosphate
0‑L | A01AA03 | olaflur | WHO Anatomical Therapeutic Chemical classification |  | olaflur
0‑L | A01AA04 | stannous fluoride | WHO Anatomical Therapeutic Chemical classification |  | stannous fluoride
0‑L | A01AA30 | combinations | WHO Anatomical Therapeutic Chemical classification |  | combinations
0‑L | A01AA51 | sodium fluoride, combinations | WHO Anatomical Therapeutic Chemical classification |  | sodium fluoride, combinations
0‑L | A01AB | Antiinfectives and antiseptics for local oral treatment | WHO Anatomical Therapeutic Chemical classification |  | Antiinfectives and antiseptics for local oral treatment
0‑L | A01AB02 | hydrogen peroxide | WHO Anatomical Therapeutic Chemical classification |  | hydrogen peroxide
0‑L | A01AB03 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification |  | chlorhexidine
0‑L | A01AB04 | amphotericin B | WHO Anatomical Therapeutic Chemical classification |  | amphotericin B
0‑L | A01AB05 | polynoxylin | WHO Anatomical Therapeutic Chemical classification |  | polynoxylin
0‑L | A01AB06 | domiphen | WHO Anatomical Therapeutic Chemical classification |  | domiphen
0‑L | A01AB07 | oxyquinoline | WHO Anatomical Therapeutic Chemical classification |  | oxyquinoline
0‑L | A01AB08 | neomycin | WHO Anatomical Therapeutic Chemical classification |  | neomycin
0‑L | A01AB09 | miconazole | WHO Anatomical Therapeutic Chemical classification |  | miconazole
0‑L | A01AB10 | natamycin | WHO Anatomical Therapeutic Chemical classification |  | natamycin
0‑L | A01AB11 | various | WHO Anatomical Therapeutic Chemical classification |  | various
0‑L | A01AB12 | hexetidine | WHO Anatomical Therapeutic Chemical classification |  | hexetidine
0‑L | A01AB13 | tetracycline | WHO Anatomical Therapeutic Chemical classification |  | tetracycline
0‑L | A01AB14 | benzoxonium chloride | WHO Anatomical Therapeutic Chemical classification |  | benzoxonium chloride
0‑L | A01AB15 | tibezonium iodide | WHO Anatomical Therapeutic Chemical classification |  | tibezonium iodide
0‑L | A01AB16 | mepartricin | WHO Anatomical Therapeutic Chemical classification |  | mepartricin
0‑L | A01AB17 | metronidazole | WHO Anatomical Therapeutic Chemical classification |  | metronidazole
0‑L | A01AB18 | clotrimazole | WHO Anatomical Therapeutic Chemical classification |  | clotrimazole
0‑L | A01AB19 | sodium perborate | WHO Anatomical Therapeutic Chemical classification |  | sodium perborate
0‑L | A01AB21 | chlortetracycline | WHO Anatomical Therapeutic Chemical classification |  | chlortetracycline
0‑L | A01AB22 | doxycycline | WHO Anatomical Therapeutic Chemical classification |  | doxycycline
0‑L | A01AB23 | minocycline | WHO Anatomical Therapeutic Chemical classification |  | minocycline
0‑L | A01AC | Corticosteroids for local oral treatment | WHO Anatomical Therapeutic Chemical classification |  | Corticosteroids for local oral treatment
0‑L | A01AC01 | triamcinolone | WHO Anatomical Therapeutic Chemical classification |  | triamcinolone
0‑L | A01AC02 | dexamethasone | WHO Anatomical Therapeutic Chemical classification |  | dexamethasone
0‑L | A01AC03 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification |  | hydrocortisone
0‑L | A01AC54 | prednisolone, combinations | WHO Anatomical Therapeutic Chemical classification |  | prednisolone, combinations
0‑L | A01AD | Other agents for local oral treatment | WHO Anatomical Therapeutic Chemical classification |  | Other agents for local oral treatment
0‑L | A01AD01 | epinephrine | WHO Anatomical Therapeutic Chemical classification |  | epinephrine
0‑L | A01AD02 | benzydamine | WHO Anatomical Therapeutic Chemical classification |  | benzydamine
0‑L | A01AD05 | acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification |  | acetylsalicylic acid
0‑L | A01AD06 | adrenalone | WHO Anatomical Therapeutic Chemical classification |  | adrenalone
0‑L | A01AD07 | amlexanox | WHO Anatomical Therapeutic Chemical classification |  | amlexanox
0‑L | A01AD08 | becaplermin | WHO Anatomical Therapeutic Chemical classification |  | becaplermin
0‑L | A01AD11 | various | WHO Anatomical Therapeutic Chemical classification |  | various
0‑L | A02 | DRUGS FOR ACID RELATED DISORDERS | WHO Anatomical Therapeutic Chemical classification |  | DRUGS FOR ACID RELATED DISORDERS
0‑L | A02A | ANTACIDS | WHO Anatomical Therapeutic Chemical classification |  | ANTACIDS
0‑L | A02AA | Magnesium compounds | WHO Anatomical Therapeutic Chemical classification |  | Magnesium compounds
0‑L | A02AA01 | magnesium carbonate | WHO Anatomical Therapeutic Chemical classification |  | magnesium carbonate
0‑L | A02AA02 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification |  | magnesium oxide
0‑L | A02AA03 | magnesium peroxide | WHO Anatomical Therapeutic Chemical classification |  | magnesium peroxide
0‑L | A02AA04 | magnesium hydroxide | WHO Anatomical Therapeutic Chemical classification |  | magnesium hydroxide
0‑L | A02AA05 | magnesium silicate | WHO Anatomical Therapeutic Chemical classification |  | magnesium silicate
0‑L | A02AA10 | combinations | WHO Anatomical Therapeutic Chemical classification |  | combinations
0‑L | A02AB | Aluminium compounds | WHO Anatomical Therapeutic Chemical classification |  | Aluminium compounds
0‑L | A02AB01 | aluminium hydroxide | WHO Anatomical Therapeutic Chemical classification |  | aluminium hydroxide
0‑L | A02AB02 | algeldrate | WHO Anatomical Therapeutic Chemical classification |  | algeldrate
0‑L | A02AB03 | aluminium phosphate | WHO Anatomical Therapeutic Chemical classification |  | aluminium phosphate
0‑L | A02AB04 | dihydroxialumini sodium carbonate | WHO Anatomical Therapeutic Chemical classification |  | dihydroxialumini sodium carbonate
0‑L | A02AB05 | aluminium acetoacetate | WHO Anatomical Therapeutic Chemical classification |  | aluminium acetoacetate
0‑L | A02AB06 | aloglutamol | WHO Anatomical Therapeutic Chemical classification |  | aloglutamol
0‑L | A02AB07 | aluminium glycinate | WHO Anatomical Therapeutic Chemical classification |  | aluminium glycinate
0‑L | A02AB10 | combinations | WHO Anatomical Therapeutic Chemical classification |  | combinations
0‑L | A02AC | Calcium compounds | WHO Anatomical Therapeutic Chemical classification |  | Calcium compounds
0‑L | A02AC01 | calcium carbonate | WHO Anatomical Therapeutic Chemical classification |  | calcium carbonate
0‑L | A02AC02 | calcium silicate | WHO Anatomical Therapeutic Chemical classification |  | calcium silicate
0‑L | A02AC10 | combinations | WHO Anatomical Therapeutic Chemical classification |  | combinations
0‑L | A02AD | Combinations and complexes of aluminium, calcium and magnesium compounds | WHO Anatomical Therapeutic Chemical classification |  | Combinations and complexes of aluminium, calcium and magnesium compounds
0‑L | A02AD01 | ordinary salt combinations | WHO Anatomical Therapeutic Chemical classification |  | ordinary salt combinations
0‑L | A02AD02 | magaldrate | WHO Anatomical Therapeutic Chemical classification |  | magaldrate
0‑L | A02AD03 | almagate | WHO Anatomical Therapeutic Chemical classification |  | almagate
0‑L | A02AD04 | hydrotalcite | WHO Anatomical Therapeutic Chemical classification |  | hydrotalcite
0‑L | A02AD05 | almasilate | WHO Anatomical Therapeutic Chemical classification |  | almasilate
0‑L | A02AF | Antacids with antiflatulents | WHO Anatomical Therapeutic Chemical classification |  | Antacids with antiflatulents
0‑L | A02AF01 | magaldrate and antiflatulents | WHO Anatomical Therapeutic Chemical classification |  | magaldrate and antiflatulents
0‑L | A02AF02 | ordinary salt combinations and antiflatulents | WHO Anatomical Therapeutic Chemical classification |  | ordinary salt combinations and antiflatulents
0‑L | A02AG | Antacids with antispasmodics | WHO Anatomical Therapeutic Chemical classification |  | Antacids with antispasmodics
0‑L | A02AH | Antacids with sodium bicarbonate | WHO Anatomical Therapeutic Chemical classification |  | Antacids with sodium bicarbonate
0‑L | A02AX | Antacids, other combinations | WHO Anatomical Therapeutic Chemical classification |  | Antacids, other combinations
0‑L | A02B | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) | WHO Anatomical Therapeutic Chemical classification |  | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
0‑L | A02BA | H2-receptor antagonists | WHO Anatomical Therapeutic Chemical classification |  | H2-receptor antagonists
0‑L | A02BA01 | cimetidine | WHO Anatomical Therapeutic Chemical classification |  | cimetidine
0‑L | A02BA02 | ranitidine | WHO Anatomical Therapeutic Chemical classification |  | ranitidine
0‑L | A02BA03 | famotidine | WHO Anatomical Therapeutic Chemical classification |  | famotidine
0‑L | A02BA04 | nizatidine | WHO Anatomical Therapeutic Chemical classification |  | nizatidine
0‑L | A02BA05 | niperotidine | WHO Anatomical Therapeutic Chemical classification |  | niperotidine
0‑L | A02BA06 | roxatidine | WHO Anatomical Therapeutic Chemical classification |  | roxatidine
0‑L | A02BA07 | ranitidine bismuth citrate | WHO Anatomical Therapeutic Chemical classification |  | ranitidine bismuth citrate
0‑L | A02BA08 | lafutidine | WHO Anatomical Therapeutic Chemical classification |  | lafutidine
0‑L | A02BA51 | cimetidine, combinations | WHO Anatomical Therapeutic Chemical classification |  | cimetidine, combinations
0‑L | A02BA53 | famotidine, combinations | WHO Anatomical Therapeutic Chemical classification |  | famotidine, combinations
0‑L | A02BB | Prostaglandins | WHO Anatomical Therapeutic Chemical classification |  | Prostaglandins
0‑L | A02BB01 | misoprostol | WHO Anatomical Therapeutic Chemical classification |  | misoprostol
0‑L | A02BB02 | enprostil | WHO Anatomical Therapeutic Chemical classification |  | enprostil
0‑L | A02BC | Proton pump inhibitors | WHO Anatomical Therapeutic Chemical classification |  | Proton pump inhibitors
0‑L | A02BC01 | omeprazole | WHO Anatomical Therapeutic Chemical classification |  | omeprazole
0‑L | A02BC02 | pantoprazole | WHO Anatomical Therapeutic Chemical classification |  | pantoprazole
0‑L | A02BC03 | lansoprazole | WHO Anatomical Therapeutic Chemical classification |  | lansoprazole
0‑L | A02BC04 | rabeprazole | WHO Anatomical Therapeutic Chemical classification |  | rabeprazole
0‑L | A02BC05 | esomeprazole | WHO Anatomical Therapeutic Chemical classification |  | esomeprazole
0‑L | A02BC06 | dexlansoprazole | WHO Anatomical Therapeutic Chemical classification |  | dexlansoprazole
0‑L | A02BC07 | dexrabeprazole | WHO Anatomical Therapeutic Chemical classification |  | dexrabeprazole
0‑L | A02BC53 | lansoprazole, combinations | WHO Anatomical Therapeutic Chemical classification |  | lansoprazole, combinations
0‑L | A02BC54 | rabeprazole, combinations | WHO Anatomical Therapeutic Chemical classification |  | rabeprazole, combinations
0‑L | A02BD | Combinations for eradication of Helicobacter pylori | WHO Anatomical Therapeutic Chemical classification |  | Combinations for eradication of Helicobacter pylori
0‑L | A02BD01 | omeprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification |  | omeprazole, amoxicillin and metronidazole
0‑L | A02BD02 | lansoprazole, tetracycline and metronidazole | WHO Anatomical Therapeutic Chemical classification |  | lansoprazole, tetracycline and metronidazole
0‑L | A02BD03 | lansoprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification |  | lansoprazole, amoxicillin and metronidazole
0‑L | A02BD04 | pantoprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification |  | pantoprazole, amoxicillin and clarithromycin
0‑L | A02BD05 | omeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification |  | omeprazole, amoxicillin and clarithromycin
0‑L | A02BD06 | esomeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification |  | esomeprazole, amoxicillin and clarithromycin
0‑L | A02BD07 | lansoprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification |  | lansoprazole, amoxicillin and clarithromycin
0‑L | A02BD08 | bismuth subcitrate, tetracycline and metronidazole | WHO Anatomical Therapeutic Chemical classification |  | bismuth subcitrate, tetracycline and metronidazole
0‑L | A02BD09 | lansoprazole, clarithromycin and tinidazole | WHO Anatomical Therapeutic Chemical classification |  | lansoprazole, clarithromycin and tinidazole
0‑L | A02BD10 | lansoprazole, amoxicillin and levofloxacin | WHO Anatomical Therapeutic Chemical classification |  | lansoprazole, amoxicillin and levofloxacin
0‑L | A02BD11 | pantoprazole, amoxicillin, clarithromycin and metronidazole | WHO Anatomical Therapeutic Chemical classification |  | pantoprazole, amoxicillin, clarithromycin and metronidazole
0‑L | A02BX | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | WHO Anatomical Therapeutic Chemical classification |  | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
0‑L | A02BX01 | carbenoxolone | WHO Anatomical Therapeutic Chemical classification |  | carbenoxolone
0‑L | A02BX02 | sucralfate | WHO Anatomical Therapeutic Chemical classification |  | sucralfate
0‑L | A02BX03 | pirenzepine | WHO Anatomical Therapeutic Chemical classification |  | pirenzepine
0‑L | A02BX04 | methiosulfonium chloride | WHO Anatomical Therapeutic Chemical classification |  | methiosulfonium chloride
0‑L | A02BX05 | bismuth subcitrate | WHO Anatomical Therapeutic Chemical classification |  | bismuth subcitrate
0‑L | A02BX06 | proglumide | WHO Anatomical Therapeutic Chemical classification |  | proglumide
0‑L | A02BX07 | gefarnate | WHO Anatomical Therapeutic Chemical classification |  | gefarnate
0‑L | A02BX08 | sulglicotide | WHO Anatomical Therapeutic Chemical classification |  | sulglicotide
0‑L | A02BX09 | acetoxolone | WHO Anatomical Therapeutic Chemical classification |  | acetoxolone
0‑L | A02BX10 | zolimidine | WHO Anatomical Therapeutic Chemical classification |  | zolimidine
0‑L | A02BX11 | troxipide | WHO Anatomical Therapeutic Chemical classification |  | troxipide
0‑L | A02BX12 | bismuth subnitrate | WHO Anatomical Therapeutic Chemical classification |  | bismuth subnitrate
0‑L | A02BX13 | alginic acid | WHO Anatomical Therapeutic Chemical classification |  | alginic acid
0‑L | A02BX51 | carbenoxolone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | carbenoxolone, combinations excl. psycholeptics
0‑L | A02BX71 | carbenoxolone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | carbenoxolone, combinations with psycholeptics
0‑L | A02BX77 | gefarnate, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | gefarnate, combinations with psycholeptics
0‑L | A02X | OTHER DRUGS FOR ACID RELATED DISORDERS | WHO Anatomical Therapeutic Chemical classification |  | OTHER DRUGS FOR ACID RELATED DISORDERS
0‑L | A03 | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | WHO Anatomical Therapeutic Chemical classification |  | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
0‑L | A03A | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | WHO Anatomical Therapeutic Chemical classification |  | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
0‑L | A03AA | Synthetic anticholinergics, esters with tertiary amino group | WHO Anatomical Therapeutic Chemical classification |  | Synthetic anticholinergics, esters with tertiary amino group
0‑L | A03AA01 | oxyphencyclimine | WHO Anatomical Therapeutic Chemical classification |  | oxyphencyclimine
0‑L | A03AA03 | camylofin | WHO Anatomical Therapeutic Chemical classification |  | camylofin
0‑L | A03AA04 | mebeverine | WHO Anatomical Therapeutic Chemical classification |  | mebeverine
0‑L | A03AA05 | trimebutine | WHO Anatomical Therapeutic Chemical classification |  | trimebutine
0‑L | A03AA06 | rociverine | WHO Anatomical Therapeutic Chemical classification |  | rociverine
0‑L | A03AA07 | dicycloverine | WHO Anatomical Therapeutic Chemical classification |  | dicycloverine
0‑L | A03AA08 | dihexyverine | WHO Anatomical Therapeutic Chemical classification |  | dihexyverine
0‑L | A03AA09 | difemerine | WHO Anatomical Therapeutic Chemical classification |  | difemerine
0‑L | A03AA30 | piperidolate | WHO Anatomical Therapeutic Chemical classification |  | piperidolate
0‑L | A03AB | Synthetic anticholinergics, quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification |  | Synthetic anticholinergics, quaternary ammonium compounds
0‑L | A03AB01 | benzilone | WHO Anatomical Therapeutic Chemical classification |  | benzilone
0‑L | A03AB02 | glycopyrronium bromide | WHO Anatomical Therapeutic Chemical classification |  | glycopyrronium bromide
0‑L | A03AB03 | oxyphenonium | WHO Anatomical Therapeutic Chemical classification |  | oxyphenonium
0‑L | A03AB04 | penthienate | WHO Anatomical Therapeutic Chemical classification |  | penthienate
0‑L | A03AB05 | propantheline | WHO Anatomical Therapeutic Chemical classification |  | propantheline
0‑L | A03AB06 | otilonium bromide | WHO Anatomical Therapeutic Chemical classification |  | otilonium bromide
0‑L | A03AB07 | methantheline | WHO Anatomical Therapeutic Chemical classification |  | methantheline
0‑L | A03AB08 | tridihexethyl | WHO Anatomical Therapeutic Chemical classification |  | tridihexethyl
0‑L | A03AB09 | isopropamide | WHO Anatomical Therapeutic Chemical classification |  | isopropamide
0‑L | A03AB10 | hexocyclium | WHO Anatomical Therapeutic Chemical classification |  | hexocyclium
0‑L | A03AB11 | poldine | WHO Anatomical Therapeutic Chemical classification |  | poldine
0‑L | A03AB12 | mepenzolate | WHO Anatomical Therapeutic Chemical classification |  | mepenzolate
0‑L | A03AB13 | bevonium | WHO Anatomical Therapeutic Chemical classification |  | bevonium
0‑L | A03AB14 | pipenzolate | WHO Anatomical Therapeutic Chemical classification |  | pipenzolate
0‑L | A03AB15 | diphemanil | WHO Anatomical Therapeutic Chemical classification |  | diphemanil
0‑L | A03AB16 | (2-benzhydryloxyethyl)diethyl-methylammonium iodide | WHO Anatomical Therapeutic Chemical classification |  | (2-benzhydryloxyethyl)diethyl-methylammonium iodide
0‑L | A03AB17 | tiemonium iodide | WHO Anatomical Therapeutic Chemical classification |  | tiemonium iodide
0‑L | A03AB18 | prifinium bromide | WHO Anatomical Therapeutic Chemical classification |  | prifinium bromide
0‑L | A03AB19 | timepidium bromide | WHO Anatomical Therapeutic Chemical classification |  | timepidium bromide
0‑L | A03AB21 | fenpiverinium | WHO Anatomical Therapeutic Chemical classification |  | fenpiverinium
0‑L | A03AB53 | oxyphenonium, combinations | WHO Anatomical Therapeutic Chemical classification |  | oxyphenonium, combinations
0‑L | A03AC | Synthetic antispasmodics, amides with tertiary amines | WHO Anatomical Therapeutic Chemical classification |  | Synthetic antispasmodics, amides with tertiary amines
0‑L | A03AC02 | dimethylaminopropionylphenothiazine | WHO Anatomical Therapeutic Chemical classification |  | dimethylaminopropionylphenothiazine
0‑L | A03AC04 | nicofetamide | WHO Anatomical Therapeutic Chemical classification |  | nicofetamide
0‑L | A03AC05 | tiropramide | WHO Anatomical Therapeutic Chemical classification |  | tiropramide
0‑L | A03AD | Papaverine and derivatives | WHO Anatomical Therapeutic Chemical classification |  | Papaverine and derivatives
0‑L | A03AD01 | papaverine | WHO Anatomical Therapeutic Chemical classification |  | papaverine
0‑L | A03AD02 | drotaverine | WHO Anatomical Therapeutic Chemical classification |  | drotaverine
0‑L | A03AD30 | moxaverine | WHO Anatomical Therapeutic Chemical classification |  | moxaverine
0‑L | A03AE | Serotonin receptor antagonists | WHO Anatomical Therapeutic Chemical classification |  | Serotonin receptor antagonists
0‑L | A03AE01 | alosetron | WHO Anatomical Therapeutic Chemical classification |  | alosetron
0‑L | A03AE03 | cilansetron | WHO Anatomical Therapeutic Chemical classification |  | cilansetron
0‑L | A03AX | Other drugs for functional gastrointestinal disorders | WHO Anatomical Therapeutic Chemical classification |  | Other drugs for functional gastrointestinal disorders
0‑L | A03AX01 | fenpiprane | WHO Anatomical Therapeutic Chemical classification |  | fenpiprane
0‑L | A03AX02 | diisopromine | WHO Anatomical Therapeutic Chemical classification |  | diisopromine
0‑L | A03AX03 | chlorbenzoxamine | WHO Anatomical Therapeutic Chemical classification |  | chlorbenzoxamine
0‑L | A03AX04 | pinaverium | WHO Anatomical Therapeutic Chemical classification |  | pinaverium
0‑L | A03AX05 | fenoverine | WHO Anatomical Therapeutic Chemical classification |  | fenoverine
0‑L | A03AX06 | idanpramine | WHO Anatomical Therapeutic Chemical classification |  | idanpramine
0‑L | A03AX07 | proxazole | WHO Anatomical Therapeutic Chemical classification |  | proxazole
0‑L | A03AX08 | alverine | WHO Anatomical Therapeutic Chemical classification |  | alverine
0‑L | A03AX09 | trepibutone | WHO Anatomical Therapeutic Chemical classification |  | trepibutone
0‑L | A03AX10 | isometheptene | WHO Anatomical Therapeutic Chemical classification |  | isometheptene
0‑L | A03AX11 | caroverine | WHO Anatomical Therapeutic Chemical classification |  | caroverine
0‑L | A03AX12 | phloroglucinol | WHO Anatomical Therapeutic Chemical classification |  | phloroglucinol
0‑L | A03AX13 | silicones | WHO Anatomical Therapeutic Chemical classification |  | silicones
0‑L | A03AX14 | valethamate | WHO Anatomical Therapeutic Chemical classification |  | valethamate
0‑L | A03AX30 | trimethyldiphenylpropylamine | WHO Anatomical Therapeutic Chemical classification |  | trimethyldiphenylpropylamine
0‑L | A03AX58 | alverine, combinations | WHO Anatomical Therapeutic Chemical classification |  | alverine, combinations
0‑L | A03B | BELLADONNA AND DERIVATIVES, PLAIN | WHO Anatomical Therapeutic Chemical classification |  | BELLADONNA AND DERIVATIVES, PLAIN
0‑L | A03BA | Belladonna alkaloids, tertiary amines | WHO Anatomical Therapeutic Chemical classification |  | Belladonna alkaloids, tertiary amines
0‑L | A03BA01 | atropine | WHO Anatomical Therapeutic Chemical classification |  | atropine
0‑L | A03BA03 | hyoscyamine | WHO Anatomical Therapeutic Chemical classification |  | hyoscyamine
0‑L | A03BA04 | belladonna total alkaloids | WHO Anatomical Therapeutic Chemical classification |  | belladonna total alkaloids
0‑L | A03BB | Belladonna alkaloids, semisynthetic, quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification |  | Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
0‑L | A03BB01 | butylscopolamine | WHO Anatomical Therapeutic Chemical classification |  | butylscopolamine
0‑L | A03BB02 | methylatropine | WHO Anatomical Therapeutic Chemical classification |  | methylatropine
0‑L | A03BB03 | methylscopolamine | WHO Anatomical Therapeutic Chemical classification |  | methylscopolamine
0‑L | A03BB04 | fentonium | WHO Anatomical Therapeutic Chemical classification |  | fentonium
0‑L | A03BB05 | cimetropium bromide | WHO Anatomical Therapeutic Chemical classification |  | cimetropium bromide
0‑L | A03C | ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS | WHO Anatomical Therapeutic Chemical classification |  | ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS
0‑L | A03CA | Synthetic anticholinergic agents in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | Synthetic anticholinergic agents in combination with psycholeptics
0‑L | A03CA01 | isopropamide and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | isopropamide and psycholeptics
0‑L | A03CA02 | clidinium and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | clidinium and psycholeptics
0‑L | A03CA03 | oxyphencyclimine and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | oxyphencyclimine and psycholeptics
0‑L | A03CA04 | otilonium bromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | otilonium bromide and psycholeptics
0‑L | A03CA05 | glycopyrronium bromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | glycopyrronium bromide and psycholeptics
0‑L | A03CA06 | bevonium and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | bevonium and psycholeptics
0‑L | A03CA07 | ambutonium and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | ambutonium and psycholeptics
0‑L | A03CA08 | diphemanil and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | diphemanil and psycholeptics
0‑L | A03CA09 | pipenzolate and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | pipenzolate and psycholeptics
0‑L | A03CA30 | emepronium and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | emepronium and psycholeptics
0‑L | A03CA34 | propantheline and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | propantheline and psycholeptics
0‑L | A03CB | Belladonna and derivatives in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | Belladonna and derivatives in combination with psycholeptics
0‑L | A03CB01 | methylscopolamine and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | methylscopolamine and psycholeptics
0‑L | A03CB02 | belladonna total alkaloids and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | belladonna total alkaloids and psycholeptics
0‑L | A03CB03 | atropine and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | atropine and psycholeptics
0‑L | A03CB04 | methylhomatropine and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | methylhomatropine and psycholeptics
0‑L | A03CB31 | hyoscyamine and psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | hyoscyamine and psycholeptics
0‑L | A03CC | Other antispasmodics in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification |  | Other antispasmodics in combination with psycholeptics
0‑L | A03D | ANTISPASMODICS IN COMBINATION WITH ANALGESICS | WHO Anatomical Therapeutic Chemical classification |  | ANTISPASMODICS IN COMBINATION WITH ANALGESICS
0‑L | A03DA | Synthetic anticholinergic agents in combination with analgesics | WHO Anatomical Therapeutic Chemical classification |  | Synthetic anticholinergic agents in combination with analgesics
0‑L | A03DA01 | tropenzilone and analgesics | WHO Anatomical Therapeutic Chemical classification |  | tropenzilone and analgesics
0‑L | A03DA02 | pitofenone and analgesics | WHO Anatomical Therapeutic Chemical classification |  | pitofenone and analgesics
0‑L | A03DA03 | bevonium and analgesics | WHO Anatomical Therapeutic Chemical classification |  | bevonium and analgesics
0‑L | A03DA04 | ciclonium and analgesics | WHO Anatomical Therapeutic Chemical classification |  | ciclonium and analgesics
0‑L | A03DA05 | camylofin and analgesics | WHO Anatomical Therapeutic Chemical classification |  | camylofin and analgesics
0‑L | A03DA06 | trospium and analgesics | WHO Anatomical Therapeutic Chemical classification |  | trospium and analgesics
0‑L | A03DA07 | tiemonium iodide and analgesics | WHO Anatomical Therapeutic Chemical classification |  | tiemonium iodide and analgesics
0‑L | A03DB | Belladonna and derivatives in combination with analgesics | WHO Anatomical Therapeutic Chemical classification |  | Belladonna and derivatives in combination with analgesics
0‑L | A03DB04 | butylscopolamine and analgesics | WHO Anatomical Therapeutic Chemical classification |  | butylscopolamine and analgesics
0‑L | A03DC | Other antispasmodics in combination with analgesics | WHO Anatomical Therapeutic Chemical classification |  | Other antispasmodics in combination with analgesics
0‑L | A03E | ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS | WHO Anatomical Therapeutic Chemical classification |  | ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS
0‑L | A03EA | Antispasmodics, psycholeptics and analgesics in combination | WHO Anatomical Therapeutic Chemical classification |  | Antispasmodics, psycholeptics and analgesics in combination
0‑L | A03ED | Antispasmodics in combination with other drugs | WHO Anatomical Therapeutic Chemical classification |  | Antispasmodics in combination with other drugs
0‑L | A03F | PROPULSIVES | WHO Anatomical Therapeutic Chemical classification |  | PROPULSIVES
0‑L | A03FA | Propulsives | WHO Anatomical Therapeutic Chemical classification |  | Propulsives
0‑L | A03FA01 | metoclopramide | WHO Anatomical Therapeutic Chemical classification |  | metoclopramide
0‑L | A03FA02 | cisapride | WHO Anatomical Therapeutic Chemical classification |  | cisapride
0‑L | A03FA03 | domperidone | WHO Anatomical Therapeutic Chemical classification |  | domperidone
0‑L | A03FA04 | bromopride | WHO Anatomical Therapeutic Chemical classification |  | bromopride
0‑L | A03FA05 | alizapride | WHO Anatomical Therapeutic Chemical classification |  | alizapride
0‑L | A03FA06 | clebopride | WHO Anatomical Therapeutic Chemical classification |  | clebopride
0‑L | A03FA07 | itopride | WHO Anatomical Therapeutic Chemical classification |  | itopride
0‑L | A03FA08 | cinitapride | WHO Anatomical Therapeutic Chemical classification |  | cinitapride
0‑L | A04 | ANTIEMETICS AND ANTINAUSEANTS | WHO Anatomical Therapeutic Chemical classification |  | ANTIEMETICS AND ANTINAUSEANTS
0‑L | A04A | ANTIEMETICS AND ANTINAUSEANTS | WHO Anatomical Therapeutic Chemical classification |  | ANTIEMETICS AND ANTINAUSEANTS
0‑L | A04AA | Serotonin (5HT3) antagonists | WHO Anatomical Therapeutic Chemical classification |  | Serotonin (5HT3) antagonists
0‑L | A04AA01 | ondansetron | WHO Anatomical Therapeutic Chemical classification |  | ondansetron
0‑L | A04AA02 | granisetron | WHO Anatomical Therapeutic Chemical classification |  | granisetron
0‑L | A04AA03 | tropisetron | WHO Anatomical Therapeutic Chemical classification |  | tropisetron
0‑L | A04AA04 | dolasetron | WHO Anatomical Therapeutic Chemical classification |  | dolasetron
0‑L | A04AA05 | palonosetron | WHO Anatomical Therapeutic Chemical classification |  | palonosetron
0‑L | A04AA55 | palonosetron, combinations | WHO Anatomical Therapeutic Chemical classification |  | palonosetron, combinations
0‑L | A04AD | Other antiemetics | WHO Anatomical Therapeutic Chemical classification |  | Other antiemetics
0‑L | A04AD01 | scopolamine | WHO Anatomical Therapeutic Chemical classification |  | scopolamine
0‑L | A04AD02 | cerium oxalate | WHO Anatomical Therapeutic Chemical classification |  | cerium oxalate
0‑L | A04AD04 | chlorobutanol | WHO Anatomical Therapeutic Chemical classification |  | chlorobutanol
0‑L | A04AD05 | metopimazine | WHO Anatomical Therapeutic Chemical classification |  | metopimazine
0‑L | A04AD10 | dronabinol | WHO Anatomical Therapeutic Chemical classification |  | dronabinol
0‑L | A04AD11 | nabilone | WHO Anatomical Therapeutic Chemical classification |  | nabilone
0‑L | A04AD12 | aprepitant | WHO Anatomical Therapeutic Chemical classification |  | aprepitant
0‑L | A04AD13 | casopitant | WHO Anatomical Therapeutic Chemical classification |  | casopitant
0‑L | A04AD14 | rolapitant | WHO Anatomical Therapeutic Chemical classification |  | rolapitant
0‑L | A04AD51 | scopolamine, combinations | WHO Anatomical Therapeutic Chemical classification |  | scopolamine, combinations
0‑L | A04AD54 | chlorobutanol, combinations | WHO Anatomical Therapeutic Chemical classification |  | chlorobutanol, combinations
0‑L | A05 | BILE AND LIVER THERAPY | WHO Anatomical Therapeutic Chemical classification |  | BILE AND LIVER THERAPY
0‑L | A05A | BILE THERAPY | WHO Anatomical Therapeutic Chemical classification |  | BILE THERAPY
0‑L | A05AA | Bile acid preparations | WHO Anatomical Therapeutic Chemical classification |  | Bile acid preparations
0‑L | A05AA01 | chenodeoxycholic acid | WHO Anatomical Therapeutic Chemical classification |  | chenodeoxycholic acid
0‑L | A05AA02 | ursodeoxycholic acid | WHO Anatomical Therapeutic Chemical classification |  | ursodeoxycholic acid
0‑L | A05AA03 | cholic acid | WHO Anatomical Therapeutic Chemical classification |  | cholic acid
0‑L | A05AA04 | obeticholic acid | WHO Anatomical Therapeutic Chemical classification |  | obeticholic acid
0‑L | A05AB | Preparations for biliary tract therapy | WHO Anatomical Therapeutic Chemical classification |  | Preparations for biliary tract therapy
0‑L | A05AB01 | nicotinyl methylamide | WHO Anatomical Therapeutic Chemical classification |  | nicotinyl methylamide
0‑L | A05AX | Other drugs for bile therapy | WHO Anatomical Therapeutic Chemical classification |  | Other drugs for bile therapy
0‑L | A05AX01 | piprozolin | WHO Anatomical Therapeutic Chemical classification |  | piprozolin
0‑L | A05AX02 | hymecromone | WHO Anatomical Therapeutic Chemical classification |  | hymecromone
0‑L | A05AX03 | cyclobutyrol | WHO Anatomical Therapeutic Chemical classification |  | cyclobutyrol
0‑L | A05B | LIVER THERAPY, LIPOTROPICS | WHO Anatomical Therapeutic Chemical classification |  | LIVER THERAPY, LIPOTROPICS
0‑L | A05BA | Liver therapy | WHO Anatomical Therapeutic Chemical classification |  | Liver therapy
0‑L | A05BA01 | arginine glutamate | WHO Anatomical Therapeutic Chemical classification |  | arginine glutamate
0‑L | A05BA03 | silymarin | WHO Anatomical Therapeutic Chemical classification |  | silymarin
0‑L | A05BA04 | citiolone | WHO Anatomical Therapeutic Chemical classification |  | citiolone
0‑L | A05BA05 | epomediol | WHO Anatomical Therapeutic Chemical classification |  | epomediol
0‑L | A05BA06 | ornithine oxoglurate | WHO Anatomical Therapeutic Chemical classification |  | ornithine oxoglurate
0‑L | A05BA07 | tidiacic arginine | WHO Anatomical Therapeutic Chemical classification |  | tidiacic arginine
0‑L | A05BA08 | glycyrrhizic acid | WHO Anatomical Therapeutic Chemical classification |  | glycyrrhizic acid
0‑L | A05C | DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification |  | DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION
0‑L | A06 | DRUGS FOR CONSTIPATION | WHO Anatomical Therapeutic Chemical classification |  | DRUGS FOR CONSTIPATION
0‑L | A06A | DRUGS FOR CONSTIPATION | WHO Anatomical Therapeutic Chemical classification |  | DRUGS FOR CONSTIPATION
0‑L | A06AA | Softeners, emollients | WHO Anatomical Therapeutic Chemical classification |  | Softeners, emollients
0‑L | A06AA01 | liquid paraffin | WHO Anatomical Therapeutic Chemical classification |  | liquid paraffin
0‑L | A06AA02 | docusate sodium | WHO Anatomical Therapeutic Chemical classification |  | docusate sodium
0‑L | A06AA51 | liquid paraffin, combinations | WHO Anatomical Therapeutic Chemical classification |  | liquid paraffin, combinations
0‑L | A06AB | Contact laxatives | WHO Anatomical Therapeutic Chemical classification |  | Contact laxatives
0‑L | A06AB01 | oxyphenisatine | WHO Anatomical Therapeutic Chemical classification |  | oxyphenisatine
0‑L | A06AB02 | bisacodyl | WHO Anatomical Therapeutic Chemical classification |  | bisacodyl
0‑L | A06AB03 | dantron | WHO Anatomical Therapeutic Chemical classification |  | dantron
0‑L | A06AB04 | phenolphthalein | WHO Anatomical Therapeutic Chemical classification |  | phenolphthalein
0‑L | A06AB05 | castor oil | WHO Anatomical Therapeutic Chemical classification |  | castor oil
0‑L | A06AB06 | senna glycosides | WHO Anatomical Therapeutic Chemical classification |  | senna glycosides
0‑L | A06AB07 | cascara | WHO Anatomical Therapeutic Chemical classification |  | cascara
0‑L | A06AB08 | sodium picosulfate | WHO Anatomical Therapeutic Chemical classification |  | sodium picosulfate
0‑L | A06AB09 | bisoxatin | WHO Anatomical Therapeutic Chemical classification |  | bisoxatin
0‑L | A06AB20 | contact laxatives in combination | WHO Anatomical Therapeutic Chemical classification |  | contact laxatives in combination
0‑L | A06AB30 | contact laxatives in combination with belladonna alkaloids | WHO Anatomical Therapeutic Chemical classification |  | contact laxatives in combination with belladonna alkaloids
0‑L | A06AB52 | bisacodyl, combinations | WHO Anatomical Therapeutic Chemical classification |  | bisacodyl, combinations
0‑L | A06AB53 | dantron, combinations | WHO Anatomical Therapeutic Chemical classification |  | dantron, combinations
0‑L | A06AB56 | senna glycosides, combinations | WHO Anatomical Therapeutic Chemical classification |  | senna glycosides, combinations
0‑L | A06AB57 | cascara, combinations | WHO Anatomical Therapeutic Chemical classification |  | cascara, combinations
0‑L | A06AB58 | sodium picosulfate, combinations | WHO Anatomical Therapeutic Chemical classification |  | sodium picosulfate, combinations
0‑L | A06AC | Bulk-forming laxatives | WHO Anatomical Therapeutic Chemical classification |  | Bulk-forming laxatives
0‑L | A06AC01 | ispaghula (psylla seeds) | WHO Anatomical Therapeutic Chemical classification |  | ispaghula (psylla seeds)
0‑L | A06AC02 | ethulose | WHO Anatomical Therapeutic Chemical classification |  | ethulose
0‑L | A06AC03 | sterculia | WHO Anatomical Therapeutic Chemical classification |  | sterculia
0‑L | A06AC05 | linseed | WHO Anatomical Therapeutic Chemical classification |  | linseed
0‑L | A06AC06 | methylcellulose | WHO Anatomical Therapeutic Chemical classification |  | methylcellulose
0‑L | A06AC07 | triticum (wheat fibre) | WHO Anatomical Therapeutic Chemical classification |  | triticum (wheat fibre)
0‑L | A06AC08 | polycarbophil calcium | WHO Anatomical Therapeutic Chemical classification |  | polycarbophil calcium
0‑L | A06AC51 | ispaghula, combinations | WHO Anatomical Therapeutic Chemical classification |  | ispaghula, combinations
0‑L | A06AC53 | sterculia, combinations | WHO Anatomical Therapeutic Chemical classification |  | sterculia, combinations
0‑L | A06AC55 | linseed, combinations | WHO Anatomical Therapeutic Chemical classification |  | linseed, combinations
0‑L | A06AD | Osmotically acting laxatives | WHO Anatomical Therapeutic Chemical classification |  | Osmotically acting laxatives
0‑L | A06AD01 | magnesium carbonate | WHO Anatomical Therapeutic Chemical classification |  | magnesium carbonate
0‑L | A06AD02 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification |  | magnesium oxide
0‑L | A06AD03 | magnesium peroxide | WHO Anatomical Therapeutic Chemical classification |  | magnesium peroxide
0‑L | A06AD04 | magnesium sulfate | WHO Anatomical Therapeutic Chemical classification |  | magnesium sulfate
0‑L | A06AD10 | mineral salts in combination | WHO Anatomical Therapeutic Chemical classification |  | mineral salts in combination
0‑L | A06AD11 | lactulose | WHO Anatomical Therapeutic Chemical classification |  | lactulose
0‑L | A06AD12 | lactitol | WHO Anatomical Therapeutic Chemical classification |  | lactitol
0‑L | A06AD13 | sodium sulfate | WHO Anatomical Therapeutic Chemical classification |  | sodium sulfate
0‑L | A06AD14 | pentaerithrityl | WHO Anatomical Therapeutic Chemical classification |  | pentaerithrityl
0‑L | A06AD15 | macrogol | WHO Anatomical Therapeutic Chemical classification |  | macrogol
0‑L | A06AD16 | mannitol | WHO Anatomical Therapeutic Chemical classification |  | mannitol
0‑L | A06AD17 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification |  | sodium phosphate
0‑L | A06AD18 | sorbitol | WHO Anatomical Therapeutic Chemical classification |  | sorbitol
0‑L | A06AD19 | magnesium citrate | WHO Anatomical Therapeutic Chemical classification |  | magnesium citrate
0‑L | A06AD21 | sodium tartrate | WHO Anatomical Therapeutic Chemical classification |  | sodium tartrate
0‑L | A06AD61 | lactulose, combinations | WHO Anatomical Therapeutic Chemical classification |  | lactulose, combinations
0‑L | A06AD65 | macrogol, combinations | WHO Anatomical Therapeutic Chemical classification |  | macrogol, combinations
0‑L | A06AG | Enemas | WHO Anatomical Therapeutic Chemical classification |  | Enemas
0‑L | A06AG01 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification |  | sodium phosphate
0‑L | A06AG02 | bisacodyl | WHO Anatomical Therapeutic Chemical classification |  | bisacodyl
0‑L | A06AG03 | dantron, incl. combinations | WHO Anatomical Therapeutic Chemical classification |  | dantron, incl. combinations
0‑L | A06AG04 | glycerol | WHO Anatomical Therapeutic Chemical classification |  | glycerol
0‑L | A06AG06 | oil | WHO Anatomical Therapeutic Chemical classification |  | oil
0‑L | A06AG07 | sorbitol | WHO Anatomical Therapeutic Chemical classification |  | sorbitol
0‑L | A06AG10 | docusate sodium, incl. combinations | WHO Anatomical Therapeutic Chemical classification |  | docusate sodium, incl. combinations
0‑L | A06AG11 | sodium lauryl sulfoacetate, incl. combinations | WHO Anatomical Therapeutic Chemical classification |  | sodium lauryl sulfoacetate, incl. combinations
0‑L | A06AG20 | combinations | WHO Anatomical Therapeutic Chemical classification |  | combinations
0‑L | A06AH | Peripheral opioid receptor antagonists | WHO Anatomical Therapeutic Chemical classification |  | Peripheral opioid receptor antagonists
0‑L | A06AH01 | methylnaltrexone bromide | WHO Anatomical Therapeutic Chemical classification |  | methylnaltrexone bromide
0‑L | A06AH02 | alvimopan | WHO Anatomical Therapeutic Chemical classification |  | alvimopan
0‑L | A06AH03 | naloxegol | WHO Anatomical Therapeutic Chemical classification |  | naloxegol
0‑L | A06AH04 | naloxone | WHO Anatomical Therapeutic Chemical classification |  | naloxone
0‑L | A06AX | Other drugs for constipation | WHO Anatomical Therapeutic Chemical classification |  | Other drugs for constipation
0‑L | A06AX01 | glycerol | WHO Anatomical Therapeutic Chemical classification |  | glycerol
0‑L | A06AX02 | carbon dioxide producing drugs | WHO Anatomical Therapeutic Chemical classification |  | carbon dioxide producing drugs
0‑L | A06AX03 | lubiprostone | WHO Anatomical Therapeutic Chemical classification |  | lubiprostone
0‑L | A06AX04 | linaclotide | WHO Anatomical Therapeutic Chemical classification |  | linaclotide
0‑L | A06AX05 | prucalopride | WHO Anatomical Therapeutic Chemical classification |  | prucalopride
0‑L | A06AX06 | tegaserod | WHO Anatomical Therapeutic Chemical classification |  | tegaserod
0‑L | A07 | ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS | WHO Anatomical Therapeutic Chemical classification |  | ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
0‑L | A07A | INTESTINAL ANTIINFECTIVES | WHO Anatomical Therapeutic Chemical classification |  | INTESTINAL ANTIINFECTIVES
0‑L | A07AA | Antibiotics | WHO Anatomical Therapeutic Chemical classification |  | Antibiotics
0‑L | A07AA01 | neomycin | WHO Anatomical Therapeutic Chemical classification |  | neomycin
0‑L | A07AA02 | nystatin | WHO Anatomical Therapeutic Chemical classification |  | nystatin
0‑L | A07AA03 | natamycin | WHO Anatomical Therapeutic Chemical classification |  | natamycin
0‑L | A07AA04 | streptomycin | WHO Anatomical Therapeutic Chemical classification |  | streptomycin
0‑L | A07AA05 | polymyxin B | WHO Anatomical Therapeutic Chemical classification |  | polymyxin B
0‑L | A07AA06 | paromomycin | WHO Anatomical Therapeutic Chemical classification |  | paromomycin
0‑L | A07AA07 | amphotericin B | WHO Anatomical Therapeutic Chemical classification |  | amphotericin B
0‑L | A07AA08 | kanamycin | WHO Anatomical Therapeutic Chemical classification |  | kanamycin
0‑L | A07AA09 | vancomycin | WHO Anatomical Therapeutic Chemical classification |  | vancomycin
0‑L | A07AA10 | colistin | WHO Anatomical Therapeutic Chemical classification |  | colistin
0‑L | A07AA11 | rifaximin | WHO Anatomical Therapeutic Chemical classification |  | rifaximin
0‑L | A07AA12 | fidaxomicin | WHO Anatomical Therapeutic Chemical classification |  | fidaxomicin
0‑L | A07AA51 | neomycin, combinations | WHO Anatomical Therapeutic Chemical classification |  | neomycin, combinations
0‑L | A07AA54 | streptomycin, combinations | WHO Anatomical Therapeutic Chemical classification |  | streptomycin, combinations
0‑L | A07AB | Sulfonamides | WHO Anatomical Therapeutic Chemical classification |  | Sulfonamides
0‑L | A07AB02 | phthalylsulfathiazole | WHO Anatomical Therapeutic Chemical classification |  | phthalylsulfathiazole
0‑L | A07AB03 | sulfaguanidine | WHO Anatomical Therapeutic Chemical classification |  | sulfaguanidine
0‑L | A07AB04 | succinylsulfathiazole | WHO Anatomical Therapeutic Chemical classification |  | succinylsulfathiazole
0‑L | A07AC | Imidazole derivatives | WHO Anatomical Therapeutic Chemical classification |  | Imidazole derivatives
0‑L | A07AC01 | miconazole | WHO Anatomical Therapeutic Chemical classification |  | miconazole
0‑L | A07AX | Other intestinal antiinfectives | WHO Anatomical Therapeutic Chemical classification |  | Other intestinal antiinfectives
0‑L | A07AX01 | broxyquinoline | WHO Anatomical Therapeutic Chemical classification |  | broxyquinoline
0‑L | A07AX02 | acetarsol | WHO Anatomical Therapeutic Chemical classification |  | acetarsol
0‑L | A07AX03 | nifuroxazide | WHO Anatomical Therapeutic Chemical classification |  | nifuroxazide
0‑L | A07AX04 | nifurzide | WHO Anatomical Therapeutic Chemical classification |  | nifurzide
0‑L | A07B | INTESTINAL ADSORBENTS | WHO Anatomical Therapeutic Chemical classification |  | INTESTINAL ADSORBENTS
0‑L | A07BA | Charcoal preparations | WHO Anatomical Therapeutic Chemical classification |  | Charcoal preparations
0‑L | A07BA01 | medicinal charcoal | WHO Anatomical Therapeutic Chemical classification |  | medicinal charcoal
0‑L | A07BA51 | medicinal charcoal, combinations | WHO Anatomical Therapeutic Chemical classification |  | medicinal charcoal, combinations
0‑L | A07BB | Bismuth preparations | WHO Anatomical Therapeutic Chemical classification |  | Bismuth preparations
0‑L | A07BC | Other intestinal adsorbents | WHO Anatomical Therapeutic Chemical classification |  | Other intestinal adsorbents
0‑L | A07BC01 | pectin | WHO Anatomical Therapeutic Chemical classification |  | pectin
0‑L | A07BC02 | kaolin | WHO Anatomical Therapeutic Chemical classification |  | kaolin
0‑L | A07BC03 | crospovidone | WHO Anatomical Therapeutic Chemical classification |  | crospovidone
0‑L | A07BC04 | attapulgite | WHO Anatomical Therapeutic Chemical classification |  | attapulgite
0‑L | A07BC05 | diosmectite | WHO Anatomical Therapeutic Chemical classification |  | diosmectite
0‑L | A07BC30 | combinations | WHO Anatomical Therapeutic Chemical classification |  | combinations
0‑L | A07BC54 | attapulgite, combinations | WHO Anatomical Therapeutic Chemical classification |  | attapulgite, combinations
0‑L | A07C | ELECTROLYTES WITH CARBOHYDRATES | WHO Anatomical Therapeutic Chemical classification |  | ELECTROLYTES WITH CARBOHYDRATES
0‑L | A07CA | Oral rehydration salt formulations | WHO Anatomical Therapeutic Chemical classification |  | Oral rehydration salt formulations
0‑L | A07D | ANTIPROPULSIVES | WHO Anatomical Therapeutic Chemical classification |  | ANTIPROPULSIVES
0‑L | A07DA | Antipropulsives | WHO Anatomical Therapeutic Chemical classification |  | Antipropulsives
0‑L | A07DA01 | diphenoxylate | WHO Anatomical Therapeutic Chemical classification |  | diphenoxylate
0‑L | A07DA02 | opium | WHO Anatomical Therapeutic Chemical classification |  | opium
0‑L | A07DA03 | loperamide | WHO Anatomical Therapeutic Chemical classification |  | loperamide
0‑L | A07DA04 | difenoxin | WHO Anatomical Therapeutic Chemical classification |  | difenoxin
0‑L | A07DA05 | loperamide oxide | WHO Anatomical Therapeutic Chemical classification |  | loperamide oxide
0‑L | A07DA06 | eluxadoline | WHO Anatomical Therapeutic Chemical classification |  | eluxadoline
0‑L | A07DA52 | morphine, combinations | WHO Anatomical Therapeutic Chemical classification |  | morphine, combinations
0‑L | A07DA53 | loperamide, combinations | WHO Anatomical Therapeutic Chemical classification |  | loperamide, combinations
0‑L | A07E | INTESTINAL ANTIINFLAMMATORY AGENTS | WHO Anatomical Therapeutic Chemical classification |  | INTESTINAL ANTIINFLAMMATORY AGENTS
0‑L | A07EA | Corticosteroids acting locally | WHO Anatomical Therapeutic Chemical classification |  | Corticosteroids acting locally
0‑L | A07EA01 | prednisolone | WHO Anatomical Therapeutic Chemical classification |  | prednisolone
0‑L | A07EA02 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification |  | hydrocortisone
0‑L | A07EA03 | prednisone | WHO Anatomical Therapeutic Chemical classification |  | prednisone
0‑L | A07EA04 | betamethasone | WHO Anatomical Therapeutic Chemical classification |  | betamethasone
0‑L | A07EA05 | tixocortol | WHO Anatomical Therapeutic Chemical classification |  | tixocortol
0‑L | A07EA06 | budesonide | WHO Anatomical Therapeutic Chemical classification |  | budesonide
0‑L | A07EA07 | beclometasone | WHO Anatomical Therapeutic Chemical classification |  | beclometasone
0‑L | A07EB | Antiallergic agents, excl. corticosteroids | WHO Anatomical Therapeutic Chemical classification |  | Antiallergic agents, excl. corticosteroids
0‑L | A07EB01 | cromoglicic acid | WHO Anatomical Therapeutic Chemical classification |  | cromoglicic acid
0‑L | A07EC | Aminosalicylic acid and similar agents | WHO Anatomical Therapeutic Chemical classification |  | Aminosalicylic acid and similar agents
0‑L | A07EC01 | sulfasalazine | WHO Anatomical Therapeutic Chemical classification |  | sulfasalazine
0‑L | A07EC02 | mesalazine | WHO Anatomical Therapeutic Chemical classification |  | mesalazine
0‑L | A07EC03 | olsalazine | WHO Anatomical Therapeutic Chemical classification |  | olsalazine
0‑L | A07EC04 | balsalazide | WHO Anatomical Therapeutic Chemical classification |  | balsalazide
0‑L | A07F | ANTIDIARRHEAL MICROORGANISMS | WHO Anatomical Therapeutic Chemical classification |  | ANTIDIARRHEAL MICROORGANISMS
0‑L | A07FA | Antidiarrheal microorganisms | WHO Anatomical Therapeutic Chemical classification |  | Antidiarrheal microorganisms
0‑L | A07FA01 | lactic acid producing organisms | WHO Anatomical Therapeutic Chemical classification |  | lactic acid producing organisms
0‑L | A07FA02 | saccharomyces boulardii | WHO Anatomical Therapeutic Chemical classification |  | saccharomyces boulardii
0‑L | A07FA51 | lactic acid producing organisms, combinations | WHO Anatomical Therapeutic Chemical classification |  | lactic acid producing organisms, combinations
0‑L | A07X | OTHER ANTIDIARRHEALS | WHO Anatomical Therapeutic Chemical classification |  | OTHER ANTIDIARRHEALS
0‑L | A07XA | Other antidiarrheals | WHO Anatomical Therapeutic Chemical classification |  | Other antidiarrheals
0‑L | A07XA01 | albumin tannate | WHO Anatomical Therapeutic Chemical classification |  | albumin tannate
0‑L | A07XA02 | ceratonia | WHO Anatomical Therapeutic Chemical classification |  | ceratonia
0‑L | A07XA03 | calcium compounds | WHO Anatomical Therapeutic Chemical classification |  | calcium compounds
0‑L | A07XA04 | racecadotril | WHO Anatomical Therapeutic Chemical classification |  | racecadotril
0‑L | A07XA51 | albumin tannate, combinations | WHO Anatomical Therapeutic Chemical classification |  | albumin tannate, combinations
0‑L | A08 | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | WHO Anatomical Therapeutic Chemical classification |  | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
0‑L | A08A | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | WHO Anatomical Therapeutic Chemical classification |  | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
0‑L | A08AA | Centrally acting antiobesity products | WHO Anatomical Therapeutic Chemical classification |  | Centrally acting antiobesity products
0‑L | A08AA01 | phentermine | WHO Anatomical Therapeutic Chemical classification |  | phentermine
0‑L | A08AA02 | fenfluramine | WHO Anatomical Therapeutic Chemical classification |  | fenfluramine
0‑L | A08AA03 | amfepramone | WHO Anatomical Therapeutic Chemical classification |  | amfepramone
0‑L | A08AA04 | dexfenfluramine | WHO Anatomical Therapeutic Chemical classification |  | dexfenfluramine
0‑L | A08AA05 | mazindol | WHO Anatomical Therapeutic Chemical classification |  | mazindol
0‑L | A08AA06 | etilamfetamine | WHO Anatomical Therapeutic Chemical classification |  | etilamfetamine
0‑L | A08AA07 | cathine | WHO Anatomical Therapeutic Chemical classification |  | cathine
0‑L | A08AA08 | clobenzorex | WHO Anatomical Therapeutic Chemical classification |  | clobenzorex
0‑L | A08AA09 | mefenorex | WHO Anatomical Therapeutic Chemical classification |  | mefenorex
0‑L | A08AA10 | sibutramine | WHO Anatomical Therapeutic Chemical classification |  | sibutramine
0‑L | A08AA11 | lorcaserin | WHO Anatomical Therapeutic Chemical classification |  | lorcaserin
0‑L | A08AA56 | ephedrine, combinations | WHO Anatomical Therapeutic Chemical classification |  | ephedrine, combinations
0‑L | A08AA62 | bupropion and naltrexone | WHO Anatomical Therapeutic Chemical classification |  | bupropion and naltrexone
0‑L | A08AB | Peripherally acting antiobesity products | WHO Anatomical Therapeutic Chemical classification |  | Peripherally acting antiobesity products
0‑L | A08AB01 | orlistat | WHO Anatomical Therapeutic Chemical classification |  | orlistat
0‑L | A08AX | Other antiobesity drugs | WHO Anatomical Therapeutic Chemical classification |  | Other antiobesity drugs
0‑L | A08AX01 | rimonabant | WHO Anatomical Therapeutic Chemical classification |  | rimonabant
0‑L | A09 | DIGESTIVES, INCL. ENZYMES | WHO Anatomical Therapeutic Chemical classification |  | DIGESTIVES, INCL. ENZYMES
0‑L | A09A | DIGESTIVES, INCL. ENZYMES | WHO Anatomical Therapeutic Chemical classification |  | DIGESTIVES, INCL. ENZYMES
0‑L | A09AA | Enzyme preparations | WHO Anatomical Therapeutic Chemical classification |  | Enzyme preparations
0‑L | A09AA01 | diastase | WHO Anatomical Therapeutic Chemical classification |  | diastase
0‑L | A09AA02 | multienzymes (lipase, protease etc.) | WHO Anatomical Therapeutic Chemical classification |  | multienzymes (lipase, protease etc.)
0‑L | A09AA03 | pepsin | WHO Anatomical Therapeutic Chemical classification |  | pepsin
0‑L | A09AA04 | tilactase | WHO Anatomical Therapeutic Chemical classification |  | tilactase
0‑L | A09AB | Acid preparations | WHO Anatomical Therapeutic Chemical classification |  | Acid preparations
0‑L | A09AB01 | glutamic acid hydrochloride | WHO Anatomical Therapeutic Chemical classification |  | glutamic acid hydrochloride
0‑L | A09AB02 | betaine hydrochloride | WHO Anatomical Therapeutic Chemical classification |  | betaine hydrochloride
0‑L | A09AB03 | hydrochloric acid | WHO Anatomical Therapeutic Chemical classification |  | hydrochloric acid
0‑L | A09AB04 | citric acid | WHO Anatomical Therapeutic Chemical classification |  | citric acid
0‑L | A09AC | Enzyme and acid preparations, combinations | WHO Anatomical Therapeutic Chemical classification |  | Enzyme and acid preparations, combinations
0‑L | A09AC01 | pepsin and acid preparations | WHO Anatomical Therapeutic Chemical classification |  | pepsin and acid preparations
0‑L | A09AC02 | multienzymes and acid preparations | WHO Anatomical Therapeutic Chemical classification |  | multienzymes and acid preparations
0‑L | A10 | DRUGS USED IN DIABETES | WHO Anatomical Therapeutic Chemical classification |  | DRUGS USED IN DIABETES
0‑L | A10A | INSULINS AND ANALOGUES | WHO Anatomical Therapeutic Chemical classification |  | INSULINS AND ANALOGUES
0‑L | A10AB | Insulins and analogues for injection, fast-acting | WHO Anatomical Therapeutic Chemical classification |  | Insulins and analogues for injection, fast-acting
0‑L | A10AB01 | insulin (human) | WHO Anatomical Therapeutic Chemical classification |  | insulin (human)
0‑L | A10AB02 | insulin (beef) | WHO Anatomical Therapeutic Chemical classification |  | insulin (beef)
0‑L | A10AB03 | insulin (pork) | WHO Anatomical Therapeutic Chemical classification |  | insulin (pork)
0‑L | A10AB04 | insulin lispro | WHO Anatomical Therapeutic Chemical classification |  | insulin lispro
0‑L | A10AB05 | insulin aspart | WHO Anatomical Therapeutic Chemical classification |  | insulin aspart
0‑L | A10AB06 | insulin glulisine | WHO Anatomical Therapeutic Chemical classification |  | insulin glulisine
0‑L | A10AB30 | combinations | WHO Anatomical Therapeutic Chemical classification |  | combinations
0‑L | A10AC | Insulins and analogues for injection, intermediate-acting | WHO Anatomical Therapeutic Chemical classification |  | Insulins and analogues for injection, intermediate-acting
0‑L | A10AC01 | insulin (human) | WHO Anatomical Therapeutic Chemical classification |  | insulin (human)
0‑L | A10AC02 | insulin (beef) | WHO Anatomical Therapeutic Chemical classification |  | insulin (beef)
This value set has 6082 codes in it. In order to keep the publication size manageable, only a selection (500 codes) of the whole set of codes is shown.
Legenda: Type L=leaf, S=specializable, A=abstract, D=deprecated. NullFlavor OTH (other) suggests text in originalText. HL7 V3: NullFlavors to appear in @nullFlavor attribute instead of @code.
| XML JSON CSV SQL SVS FHIR (4.0) [xml / json]